---
title: "Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301028034.md"
description: "Indivior announced supplemental disclosures ahead of its Oct. 15 merger with Supernus, where Indivior will be renamed Supernus. The update includes revised Cantor Fitzgerald valuation ranges: $50.55–$59.50 for Supernus and $24.20–$43.90 for Indivior after a $1bn special dividend. Disclosures were added to address stockholder complaints and mitigate litigation risk, though both companies deny wrongdoing."
datetime: "2026-10-06T11:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301028034.md)
  - [en](https://longbridge.com/en/news/301028034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301028034.md)
generator: "portal-rs"
---

# Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges

**Indivior announced supplemental disclosures to its joint proxy statement with Supernus ahead of an Oct. 15 special meeting.**

**Key Highlights:**

-   Indivior will merge Merger Sub into Supernus, with Supernus surviving and Indivior to be renamed Supernus following the transaction.
-   Supplement updates Cantor Fitzgerald valuation analyses, showing Supernus implied per-share range of $50.55–$59.50.
-   Indivior dividend-adjusted implied per-share range revised to $24.20–$43.90 after adjustments including a $1bn Special Dividend.
-   Supplement filed to address stockholder demand letters and complaints; companies deny wrongdoing but voluntarily added disclosures to avoid litigation risk.

Original SEC Filing: Indivior Pharmaceuticals, Inc. \[ INDV \] - 8-K - Oct. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [INDV.US](https://longbridge.com/en/quote/INDV.US.md)
- [SUPN.US](https://longbridge.com/en/quote/SUPN.US.md)

## Related News & Research

- [Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)](https://longbridge.com/en/news/302622266.md)
- [Supernus Pharmaceuticals Holds Special Stockholder Meeting](https://longbridge.com/en/news/302018511.md)
- [BUZZ-Huron Consulting poised to hit fresh record ahead of S&P SmallCap addition](https://longbridge.com/en/news/302883892.md)
- [Indivior Pharmaceuticals announces special shareholder meeting on merger with Supernus](https://longbridge.com/en/news/301027283.md)
- [Top Indivior Insider Quietly Ramps Up Stake in Bold New Move](https://longbridge.com/en/news/297262729.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**